We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...

Clinical Trial Success at Cincinnati Children's Supports Recent US FDA Approval for First Therapy to Directly Replace a Gene in the Brain ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

In labs across America, scientists and researchers are making breakthroughs that could transform the treatment of rare diseases.

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

The field of immunological disease diagnosis has become increasingly critical due to the rise in immune-related health issues ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...